Results 11 to 20 of about 284,370 (314)

Expression Value of Rab10 in Breast Cancer

Clinical and Experimental Obstetrics & Gynecology, 2023
Background: Rab10 is a small GTPase protein belonging to the Ras superfamily. It is expressed and plays a role in a variety of malignant tumours. However, the expression of Rab10 and its role in breast cancer (BC) prognosis remains unclear.
Jian Zhuo, Yanchun Zhao, Jianjun Han, He Li, Ruiying Hao, Yan Yang, Luxian Dai, Ankang Sheng, Xiaohong Yang, Weiguang Liu   +9 more
doaj   +1 more source

Smoking history and breast cancer risk by pathological subtype: MCC-Spain study

Tobacco Induced Diseases, 2023
Introduction The role of cigarette smoking on breast cancer risk remains controversial, due to its dual carcinogenic-antiestrogenic action. Methods In the population-based multi-case-control study (MCC-Spain), we collected epidemiological and clinical ...
Belén Peñalver-Argüeso, Esther García-Esquinas, Adela Castelló, Nerea Fernández de Larrea-Baz, Gemma Castaño-Vinyals, Pilar Amiano, Tania Fernández-Villa, Marcela Guevara, Guillermo Fernández-Tardón, Juan Alguacil, Mireia Obón-Santacana, Inés Gómez-Acebo, Marina Pinto-Carbó, Rafael Marcos-Gragera, Nuria Aragonés, Amaia Aizpurua, Vicente Martín-Sánchez, Eva Ardanaz, Trinidad Dierssen-Sotos, Jose Juan Jiménez-Moleón, Manolis Kogevinas, Marina Pollán, Beatriz Pérez-Gómez   +22 more
doaj   +1 more source

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients [PDF]

BMC Cancer, 2022
Abstract Background Human epidermal growth factor receptor 2 (HER2)-positive tumors are defined by protein overexpression (3+) or gene amplification using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), respectively.
Yoshiya Horimoto, Yumiko Ishizuka, Yuko Ueki, Toru Higuchi, Atsushi Arakawa, Mitsue Saito   +5 more
openaire   +3 more sources

The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI

Indian Journal of Pathology and Microbiology, 2022
Background: Colorectal cancer (CRC) is the third most commonly occurring cancer in men and the second most common cancer in women. Despite advances in surgical techniques and chemotherapeutic regimens, CRC continues to be one of the main causes of cancer-
Ismail Saygin, Emel Cakir
doaj   +1 more source

Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer [PDF]

Korean Journal of Clinical Oncology, 2018
Purpose This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival.
Ashraf Mahmoud El-Enbaby, Nadia Ahmed Abd El Moneim, Gehan Abd El atti Khedr, Yasmine Mohamed Nagy Elwany   +3 more
doaj   +1 more source

Investigation of Chemical Compounds from Phomopsis Extract as Anti-Breast Cancer Using LC-MS/MS Analysis, Molecular Docking, and Molecular Dynamic Simulations

International Journal of Technology, 2023
Since 2014, we have successfully isolated endophytic fungi from the leaves of Indonesian Annona muricata, exhibiting potential anti-breast cancer properties.
Husnawati, Kusmardi Kusmardi, Rini Kurniasih, AE Zainal Hasan, Dimas Andrianto, Heddy Julistiono, Bambang Pontjo Priosoeryanto, I Made Artika, Mohd Nazil Salleh   +8 more
doaj   +1 more source

Bone metastases of breast cancer: The influence of hormone receptors and human epidermal growth factor receptor 2 [PDF]

Medicinski Podmladak
Breast cancer is the leading cause of cancer-related deaths among women worldwide. While significant progress has been made in the prophylaxis, diagnosis, and management of breast cancer, around 90% of deaths occur due to metastatic disease, which is ...
Rajković Stanislav, Sopta Jelena
doaj   +1 more source

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Annette Lebeau, Arnould L, Baselga J, Bast, Bilous M, Carter P, Cho HS, Clynes RA, Cobleigh MA, Connor CS, Crowder RJ, Dandachi N, De Laurentiis M, Di Leo A, Di Loreto C, Goldhirsch A, Gschwind A, Hancock MC, Hanna W, Harari D, Hortobagyi GN, Hudziak RM, Jacobs TW, Kobayashi M, Lebeau A, Lohrisch C, Mass R, Mass R, Molina MA, Mueller-Holzner E, Nagata Y, Osborne CK, Paik S, Piccart MJ, Piccart-Gebhart MJ, Pietras RJ, Pinto AE, Revillion F, Romond EP, Ross JS, Seidman AD, Sliwkowski MX, Tanner M, Taucher S, Yakes FM, Yarden Y   +45 more
core   +1 more source

Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience. [PDF]

, 2016
BackgroundHER2/neu overexpression and/or amplification has been widely studied in a number of solid tumors, primarily in the breast. In gynecologic neoplasms, determination of HER2/neu status has not been well studied as a predictive biomarker in anti ...
Apple, Sophia K, Moatamed, Neda A, Ostrzega, Nora, Rao, Jian-Yu, Sullivan, Peggy S, Woo, Jennifer S   +5 more
core   +2 more sources

Short-course adjuvant trastuzumab in breast cancer: Experience from a tertiary cancer center in rural India

Cancer Research, Statistics, and Treatment, 2020
Introduction: Majority of the patients in low-to-middle income countries (LMICs) have no access to adjuvant trastuzumab due to financial constraints. Short-course (9 weeks) schedule of trastuzumab is a feasible alternative in this setting.
Avaronnan Manuprasad, Praveen Kumar Shenoy, Joneetha Jones, N V Vinin, Adarsh Dharmarajan, Geetha Muttath   +5 more
doaj   +1 more source